Icon Plc (NASDAQ:ICLR) Receives $168.73 Average Target Price from Analysts

Shares of Icon Plc (NASDAQ:ICLR) have received a consensus recommendation of “Hold” from the sixteen research firms that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $170.40.

ICLR has been the topic of several recent research reports. Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Citigroup increased their price target on Icon from $165.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday. Truist Financial reaffirmed a “buy” rating and issued a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday. UBS Group set a $160.00 target price on shares of Icon in a report on Wednesday, June 24th. Finally, BMO Capital Markets lifted their price objective on shares of Icon from $160.00 to $187.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th.

Icon News Roundup

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
• Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
• Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
• Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript

Institutional Trading of Icon

Large investors have recently bought and sold shares of the business. Trinity Street Asset Management LLP grew its position in Icon by 27.1% in the second quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock valued at $266,725,000 after acquiring an additional 327,314 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Icon by 463.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 71,817 shares of the medical research company’s stock valued at $12,475,000 after purchasing an additional 59,078 shares in the last quarter. Polianta Ltd acquired a new position in Icon during the 2nd quarter worth approximately $1,876,000. GAMMA Investing LLC boosted its position in Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after buying an additional 69 shares in the last quarter. Finally, Grove Bank & Trust grew its stake in shares of Icon by 30.0% during the second quarter. Grove Bank & Trust now owns 866 shares of the medical research company’s stock worth $150,000 after buying an additional 200 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Stock Performance

ICLR stock opened at $163.57 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The company’s 50-day simple moving average is $156.70 and its 200 day simple moving average is $135.31. Icon has a 52 week low of $66.57 and a 52 week high of $203.91. The company has a market capitalization of $12.52 billion, a PE ratio of 38.40, a price-to-earnings-growth ratio of 8.03 and a beta of 1.21.

Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, July 29th. The medical research company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.55 by $0.01. The business had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.26 EPS. As a group, sell-side analysts anticipate that Icon will post 9.43 earnings per share for the current year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.